193 results about "Proliferative capacity" patented technology

The invention discloses mesenchymal stem cells, a screening and identifying method of lipoprotein particles secreted by the mesenchymal stem cells and application of the mesenchymal stem cells. The screening and identifying method of the mesenchymal stem cells comprises the steps of cell culture, genotype identification, multiplication capacity identification, pluripotency and self-renewal capacity identification, differentiation capacity identification, lipid droplet identification after high fat induction, APOE lipoprotein secretion capacity identification and the like. The screening and identifying method of the lipoprotein particles comprises the steps of high-fat-induced lipoprotein secretion, lipoprotein separation and purification, lipoprotein particle size identification, lipoprotein particle content identification and the like, and target cells and target lipoprotein particles can be rapidly and accurately screened through the systematic screening and identifying method. The screened target lipoprotein particles can improve the dyslipidemia of APOE4 / 4 genotype Alzheimer's disease. Compared with the prior art, the method not only can avoid the gene manipulation risk faced by APOE gene editing, but also can provide a new standard for identification of mesenchymal stem cells and lipoprotein particles secreted by the mesenchymal stem cells, and can screen wider and easier therapeutic cell sources for later application.

The invention discloses a detection method for rapid real-time drug effect evaluation and application of the detection method. The detection method comprises the following steps: providing a quantitative corresponding relation between a same-generation calibration change value of electrical characteristics caused by physiological changes such as cell same-representative characteristics and the like and the cell proliferation ability; adhering to-be-detected cells to the surface of the same membrane electrode; applying the medicine to be detected, and observing the same generation measurement change value of the electrical characteristics in a cell proliferation cycle; and based on the quantitative corresponding relationship, obtaining the drug effect of the corresponding real-time proliferation characteristic evaluation drug. According to the detection method provided by the invention, the physiological changes such as the same-representative characteristics of the adherent cells are monitored through the membrane electrode, and after the quantitative corresponding relation between the change indexes of the same-representative characteristics of the cells and the proliferation capacity of the cells is established, the cell proliferation capacity is detected; the change of the cell proliferation capacity can be predicted through physiological changes such as the same representative characteristics of the cells before proliferation and apoptosis of the cells, so that the judgment period of the influence of the medicine on the cells can be greatly shortened, and the progress of medicine evaluation and research and development can be remarkably accelerated.

The invention discloses a culture method of high-activity human urine-derived stem cells, which relates to the technical field of biological medicine, and is technically characterized by comprising the following steps: collecting urine samples of pregnant and lying-in women, coating a culture plate with gelatin, inducing adherence, performing passage amplification, performing immunofluorescence identification, performing function detection and other optimized conditions, and separating and culturing the stem cells. Compared with urine-derived stem cells of normal adults, the stem cells derived from pregnant women have stronger activity, higher dryness and faster multiplication capacity. The invention provides a novel and superior cell source for tissue engineering and regenerative medicine.

The invention relates to a serum-free culture medium for culturing mesenchymal stem cells as well as a preparation method and application of the serum-free culture medium. Wherein the serum-free culture medium comprises a complete culture medium and praeruptorin E, and the content of the praeruptorin E in the serum-free culture medium is 0.25-3 [mu] M. The inventor finds that a serum-free culture medium containing a certain concentration of praeruptorin E can effectively improve the decline of replicative activity of mesenchymal stem cells in in-vitro passage. Specifically, the serum-free culture medium containing the praeruptorin E with a certain concentration can reduce the expression level of a marker beta-galactosidase with reduced replicative activity in the mesenchymal stem cells with reduced replicative activity after multiple in-vitro passage, reduce the expression of a gene CDKN1A with reduced replicative activity, and increase the multiplication capacity of the mesenchymal stem cells; the mitochondrial damage is reduced.

The present invention discloses a low - serum medium and its application in the preparation of cultured meat from Larimichthys crocea cells, which is also applicable to other marine or freshwater fish, belonging to the field of bioengineering technology. The low - serum medium comprises a basal medium, fetal bovine serum accounting for 30 - 80 μL / mL, and exogenous additives. The exogenous additives include human serum albumin, ascorbic acid, basic fibroblast growth factor polypeptide, human holo - transferrin, lysophosphatidic acid, and human recombinant IGF - 1. Based on the DMEM / F12 medium, the low - serum medium provided by the present invention adds six substances that promote cell growth, reduces the dependence of satellite cells on fetal bovine serum, effectively reduces the usage amount of fetal bovine serum, and saves the culture cost. Compared with the general - type medium (DMEM high - glucose, adding 10% FBS), the low - serum medium provided by the present invention has an equivalent effect on the maintenance and proliferation ability of cell stem cells.

Provided herein are methods for mechanically conditioning cells to improve their proliferative function and multipotency, as well as protect them from advancing senescence. In the methods, brachial loading alone is first used to improve the efficiency of culture expansion. Once a sufficient population of healthy cells are generated, pharmacological agents are added as a cotreatment to drive differentiation into a desired phenotype. The conditioned cells may then be used to prepare compositions for administration to a patient to treat a disease.

The invention discloses a method for wrapping stem cells by adopting programmable DNA (deoxyribonucleic acid) hydrogel and application of the method, under isothermal physiological conditions, three-dimensional DNA hydrogel is formed through a hybridization chain reaction of an initiation chain (I) and hairpin structure DNA to realize reversible wrapping and release of the stem cells. The hairpin structure DNA is formed by denaturation-renaturation treatment of at least two DNA monomer building blocks, and the mechanical rigidity of the hydrogel is realized by regulating and controlling the molar ratio of the initiation chain (I) to the total amount of the DNA monomer building blocks; the DNA hydrogel can reversibly wrap and release stem cells, and the wrapped stem cells can maintain activity and dryness and recover normal multiplication capacity after being released. According to the method disclosed by the invention, the activity and dryness of the stem cells are remarkably maintained, obvious immune activation is avoided, and the method provides a brand new tool for in-vitro culture and engineering application of the stem cells and has a wide application prospect.

The invention provides a mutant spinal glioma cell line. The H3K27M mutant type glioma cell line is successfully constructed, the constructed cell line has more excellent multiplication capacity, migration capacity, tumor formation capacity and drug resistance, the curative effect and potential side effects of drugs can be more comprehensively evaluated, the cell line can be used for in-vitro research on the biological function of H3K27M glioma and response to drug treatment, and the cell line can be applied to in-vitro research of the H3K27M mutant type glioma. Wide application prospects are realized.

The invention belongs to the technical field of autoimmune skin disease immunotherapy, and provides a three-target novel chimeric autoantibody receptor structure which comprises three chimeric receptors through two connecting peptides, specifically, a first chimeric autoantibody receptor comprises a Dsg1 extracellular structural domain; the second chimeric autoantibody receptor comprises a Dsg3 extracellular structural domain; the third chimeric antigen receptor comprises an extracellular domain capable of targeting a B cell associated antigen; wherein the Dsg1 extracellular structural domain is an extracellular structural domain of desmosome core glycoprotein 1; the Dsg3 extracellular structural domain is the extracellular structural domain of desmosome core glycoprotein 3. In-vitro experiments and animal experiments verify that the novel three-target CAAR-T cells can significantly increase the release of cytokines, enhance the targeted killing activity of the cytokines, and show better multiplication capacity; a novel cellular immunotherapy technology is provided for treating autoimmune skin diseases, and the application of CAAR-T in the field of autoimmune disease treatment can be expanded.

The invention provides an immortalized NK cell line SZ093 derived from healthy human umbilical cord blood as well as a preparation method and application of the immortalized NK cell line SZ093. The immortalized NK cell line SZ093 derived from the healthy human umbilical cord blood is preserved in Guangdong Microbial Culture Collection Center on September 26, 2025, and the preservation number is GDMCC No: 67036. The immortalized NK cell line SZ093 derived from the healthy human umbilical cord blood, provided by the invention, can still keep good multiplication capacity and high survival rate in a long-time (more than one year) culture process, and has high killing capacity on tumor cells.

The invention discloses a chimeric antigen receptor double-negative T cell drug co-expressing CXCR5 and IL-7 and application thereof, the cell drug can co-express CXCR5 and IL-7, and the cell drug comprises EF1-alpha, a CD8 alpha signal peptide, an NKG2D extracellular domain, a CD8 alpha hinge region, a CD8 alpha transmembrane region, a costimulatory factor 4-1BB, a CD3 zeta intracellular signal region, T2A, a chemotactic factor receptor CXCR5, P2A and interleukin IL-7 which are connected in sequence; according to the chimeric antigen receptor double-negative T cell drug co-expressing the CXCR5 and the IL-7 and the application of the chimeric antigen receptor double-negative T cell drug, the CXCR5 and the IL-7 are co-expressed on CAR-DNT cells of targeted NKG2DL, so that the migration and infiltration capacity of the drug to a tumor site is enhanced, the survival and proliferation capacity of the CAR-T cells is improved, the killing effect of the CAR-DNT cells on tumors is improved, and the drug has a good application prospect. The purpose of treating tumors is achieved, and allogenic treatment can be achieved.

The invention discloses nucleus pulposus cells as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The method comprises the steps that exosomes are collected from immortalized spherical nucleus pulposus cells and used for culturing the nucleus pulposus cells, the cultured nucleus pulposus cells have higher multiplication capacity, and large-scale in-vitro amplification of the nucleus pulposus cells is achieved; meanwhile, the cultured nucleus pulposus cells have higher extracellular matrix secretion capacity. The cultured nucleus pulposus cells are used for treating the intervertebral disc degeneration disease, the clinical use requirement can be met, and an effective treatment scheme is provided for treating the intervertebral disc degeneration disease.

The invention relates to the field of cell engineering and gene engineering, in particular to a method for enhancing the multiplication capacity of umbilical cord mesenchymal stem cells and application. The expression or activity of the STN1 gene in the umbilical cord mesenchymal stem cells is reduced through an accelerant, and the umbilical cord mesenchymal stem cells with enhanced multiplication capacity are obtained. By knocking down the hUC-MSCs of STN1, the proliferation speed of the hUC-MSCs is higher, DNA replication is more active, the clone formation ability is higher, and the aging proportion of the hUC-MSCs can be remarkably reduced.

The invention relates to the technical field of biomedicine, and provides an efficient separation and culture method of rat meniscus fibrocartilage cells. The yield and activity of the meniscus fibrocartilage cells are improved through a step-by-step enzyme digestion technology, the primary cell adherence time is shortened to 4-6 h by optimizing culture conditions, the breakthrough of sufficiently extracting the meniscus fibrocartilage cells from a single rat is achieved, the use amount of experimental animals is greatly reduced, and the cost is reduced. Meanwhile, it is ensured that the cell activity and proliferation capacity meet the requirements of subsequent passage and functional research, and the method has remarkable advantages in the aspects of ethical compliance, cost control and experimental efficiency.

The application discloses medical use of gelated cells loaded with sulfonated chitosan in treatment of atherosclerosis, and belongs to the technical field of biological medicine. The gelated cells loaded with sulfonated chitosan take macrophages as host cells, and intracellular cross-linking forms a photocrosslinking hydrogel network composed of methacrylated hyaluronic acid and sulfonated chitosan. The gelated cells completely retain cell membrane structure and membrane surface protein expression, lose the proliferation ability, and have excellent blood lipid selective adsorption capacity and foam cell lipid metabolism regulation capacity. In-vivo and in-vitro experiments prove that the gelated cells can significantly reduce blood lipid levels of atherosclerosis model animals, reduce aortic plaque area, and have good biological safety, thereby providing a new strategy and candidate drug for prevention and treatment of atherosclerosis, and having a good clinical application prospect.

To provide: a cell culture vessel that can achieve both detachability and proliferation ability, that is, can facilitate cell detachment without reducing the proliferation ability of cells; and a cell detachment method using the cell culture vessel, provided is a cell detachment method of detaching, through use of a culture vessel having a periodic recess / protrusion pattern on a culture surface, comprising a detachment step of: causing a vibrating unit in which, when an observation image of a cross section perpendicular to the culture surface is obtained, a length Lcp of a contour of the cell on the culture surface side in a measurement region of the observation image and a length Lf of the measurement region in a direction parallel to the culture surface satisfy Lcp>Lf; and transmitting the ultrasonic vibration to the cell, to thereby detach the cell from the culture surface.

The invention belongs to the technical field of biological medicines, and particularly relates to application of dirithromycin in preparation of a product for treating LINC00516 high-expression lung adenocarcinoma. The invention discloses the effect of the long-chain non-coding RNA LINC00516 in abnormal activation of the lung adenocarcinoma cell cycle for the first time. Researches show that LINC00516 is directly combined with CDK1, the kinase activity of CDK1 is remarkably enhanced, and the inhibitory phosphorylation level of CDK1 is reduced, so that lung adenocarcinoma cells are driven to quickly enter a G2 / M phase, and tumor cell proliferation is accelerated. The invention further innovatively proposes that dirithromycin is used as an intervention means, and by blocking the combination of LINC00516 and CDK1, the activity of CDK1 is effectively reduced, and the proliferation capacity of tumor cells is inhibited. In-vivo and in-vitro experiments prove that the dirithromycin can obviously inhibit the growth of lung adenocarcinoma cells with high expression of LINC00516, so that a brand-new molecular targeting treatment strategy is provided for clinic.

The process provided in this invention transfects primary cells with gene editing reagents using a high-volume gas-permeable cell culture device and a flow-through electroporation device under conditions that improve gene editing performance, cell yield, and drug (DP) quality characteristics for cell therapy applications. As demonstrated in the examples, primary cells edited according to the process provided herein achieved improved double-strand break (DSB) formation rates, increased frequency of homology-directed repair (HR) and non-homologous end joining (NHEJ) combinations, increased frequency of bi-allelic and mono-allelic HR events, improved cell viability, proliferative capacity, and cell fitness after gene editing, and reduced manufacturing time.

The invention relates to a mesenchymal stem cell serum-free culture medium with limited chemical components as well as application and a method thereof, the serum-free culture medium is completely serum-free and has definite components: all additives are known chemical substances and meet the production requirements of cGMP (Complementary Good Manufacturing Practice); telomere shortening can be obviously delayed; replicative senescence is slowed down by activating TERT expression; the multiplication capacity can also be enhanced; the P10 generation cells still have the active division capacity; multidirectional differentiation is supported; the osteogenic differentiation efficiency is superior to that of a traditional serum-containing system; and the method is suitable for industrial production and clinical transformation.

The present invention discloses a culture medium and its application, as well as a method for in vitro isolation and culture of yak skeletal muscle satellite cells, which relates to the technical field of cell culture. The culture medium is composed of the following raw materials: fetal bovine serum with a mass fraction of 9-13%, penicillin at 95-105 U / mL, streptomycin at 95-105 μg / mL, bamboo leaf flavonoids at 5-12 μmol / L, apigenin at 20-30 μmol / L, and the balance is DMEM. The present invention mainly adds appropriate amounts of bamboo leaf flavonoids and apigenin to the culture medium. The two cooperate synergistically, significantly improving the proliferation ability of bovine skeletal muscle satellite cells, and further applying it to the in vitro isolation and culture of yak skeletal muscle satellite cells, establishing a complete and unique sterile isolation, purification, and culture system for yak skeletal muscle satellite cells, providing methods and approaches for a series of future research carried out through yak skeletal muscle satellite cells.

Provided are: a highly proliferative cell having improved cell proliferation ability; and a method for producing the highly proliferative cell. A highly proliferative cell derived from ectoderm cells, which has the characteristics of ectoderm cells and exhibits the expression behavior of A1 described below. (A1) In the highly proliferative cells, the expression level (E1) of at least one marker gene selected from the group consisting of GFAP, S100B, Musashhi1, CSPG4, Netin, and SLC1A3 exhibits the following relative value (E1 / EC) with respect to the expression level (EC) of a control gene. GFAP (E1 / EC) gt; 0.2 part; s100B (E1 / EC) gt; 0.017%, 0.017%; musashhi1 (E1 / EC) gt; 0.15, 0.15; cSPG4 (E1 / EC) lt; 0.015% of the total weight; the Nestin (E1 / EC) gt is obtained; 0.6 part; sLC1A3 (E1 / EC) gt; and 0.09%. A highly proliferative cell having the characteristics of ectoderm cells, the number of cells after a culture period of 28 days or less in contact with a low-molecular-weight signaling pathway inhibitor is more than 1.0 times the number of ectoderm cells after the same culture period under the same culture conditions except for the same culture conditions in which the cells are not in contact with the low-molecular-weight signaling pathway inhibitor.

This invention provides a chimeric antigen receptor comprising an NFIX-encoding gene, a self-cleaving peptide sequence F2A, and a CAR-encoding sequence. The NFIX-encoding gene is located upstream and is linked to the CAR-encoding sequence via the self-cleaving peptide sequence F2A. The sequence of the NFIX-encoding gene is shown in SEQ ID NO. 01, and the sequence of the self-cleaving peptide sequence F2A is shown in SEQ ID NO. 03. This invention also provides a chimeric antigen receptor T cell expressing the aforementioned chimeric antigen receptor. This invention further provides the application of the aforementioned chimeric antigen receptor or the aforementioned chimeric antigen receptor T cell in the preparation of drugs for treating cancer. This invention improves the antitumor therapeutic effect of CAR-T cells by introducing the NFIX expression element into engineered T cells, thereby enhancing their functional stability, proliferative capacity, and cytotoxic activity under continuous antigen stimulation.

The present invention relates to a method for selecting a donor source for NK cells with enhanced proliferative capacity, wherein specific single nucleotide polymorphisms (SNPs) of the CISH gene are identified. According to the present invention, in the context of cell therapy including NK cells, the method solves the problem that the efficacy of NK cells differs according to the difference of donor sources, thereby enabling the production of NK cells having excellent proliferation ability and stable quality.

The invention provides application of Mybl2 protein in preparation of a medicine for repairing heart injury, and belongs to the technical field of biological medicine. The invention provides an application of Mybl2 protein in preparation of a medicine for repairing heart injury. The medicine comprises overexpressed Mybl2 protein. Mybl2 overexpression can significantly increase the proportion of myocardial cell proliferation and promote expression of cell cycle related proteins, Mybl2 participates in maintaining the proliferation capacity of myocardial cells, and overexpression can effectively promote myocardial cell proliferation and is a potential new target for myocardial regeneration.

The invention discloses a preparation method of a purified and immortalized pilose antler stem cell line, and belongs to the technical field of biology. Comprising the following steps: S1, performing primary culture on pilose antler stem cells to obtain primary cells; s2, purifying the primary cells to obtain a purified cell strain with high multiplication capacity; and S3, carrying out natural immortalization domestication on the purified cell strain to obtain the single natural immortalization antler stem cell line. According to the method, the antler stem cells are subjected to primary culture, purification and immortalized domestication, so that the pure antler stem cell line subjected to infinite passage in a natural state can be obtained, continuous passage can be performed for more than 50 generations, the cost is effectively saved, the immortalized domestication method is realized through repeated passage, the passage is a one-passage two-passage mode, and the immortalized domestication method is simple and convenient. The repeated passage time is once every two days; meanwhile, the antler stem cell line is cloned from one cell, so that the antler stem cell line has relatively high genetic stability.

The present invention relates to the field of cell culture, and in particular to a culture medium and a culture method for stem cell-like memory T lymphocytes. By adding a GSK-3β inhibitor, an mTOR inhibitor or a PI3K inhibitor, as well as adding IL-15 and using magnetic bead sorting, the present invention can provide a large number of stem cell-like memory T lymphocytes with memory characteristics and low differentiation status, which can be used alone for tumor treatment, or as a basic cell for CAR-T treatment to obtain better anti-tumor ability and survival and proliferation ability than central memory lymphocytes or effector lymphocytes in clinical practice, which has great significance and value to the entire field of cell research and application.

The invention discloses an application of SB216763 in improving the in-vitro proliferation capacity of porcine spermatogonium. Therefore, the SB216763 can be used as an additive of the porcine spermatogonial cell in-vitro culture medium, and the porcine spermatogonial cell in-vitro culture medium combined with various growth factors is prepared. Researches show that clone groups of the porcine spermatogonium cultured by the culture medium additionally added with the SB216763 are increased, the number of the clone groups is remarkably increased, the expression quantity of genes related to proliferation is remarkably increased, apoptosis genes are remarkably reduced, and the expression of genes related to reproductive specificity and pluripotent maintenance is also increased, so that the in-vitro proliferation and long-term maintenance of the porcine spermatogonium are improved, and the porcine spermatogonium can be used for preparing a novel culture medium for the porcine spermatogonium. Therefore, the in-vitro culture level of the PSCs is systematically improved. Therefore, the invention provides a reliable basis for establishing a long-term, stable and efficient in-vitro culture system of the porcine spermatogonium, and provides a stable and efficient cell model for gene editing of the porcine spermatogonium, preparation of transgenic animals and research on reproductive diseases; the method also has potential application value in the aspects of genetic improvement of pig breeds or preservation of male germplasm resources.

The invention belongs to the technical field of biology, and relates to a hybridoma cell strain C8-3-7 and a preparation method thereof. The preservation number of the cell strain C8-3-7 is CCTCC (China Center For Type Culture Collection) No: C202573. The hybridoma cell strain C8-3-7 efficiently expresses the DHX33 antibody and has an infinite proliferation capability. The DHX33 antibody can be specifically combined with DHX33 protein, and can specifically recognize DHX33 protein antigen in ELISA (enzyme-linked immuno sorbent assay) and immunohistochemistry or immunocytochemistry analysis.